Antibody therapy for acute myeloid leukaemia

Gasiorowski, R. E., Clark, G. J., Bradstock, K. and Hart, D. N. J. (2014) Antibody therapy for acute myeloid leukaemia. British Journal of Haematology, 164 4: 481-495. doi:10.1111/bjh.12691

Author Gasiorowski, R. E.
Clark, G. J.
Bradstock, K.
Hart, D. N. J.
Title Antibody therapy for acute myeloid leukaemia
Journal name British Journal of Haematology   Check publisher's open access policy
ISSN 0007-1048
Publication date 2014-02-01
Year available 2013
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1111/bjh.12691
Open Access Status Not yet assessed
Volume 164
Issue 4
Start page 481
End page 495
Total pages 15
Place of publication West Sussex, United Kingdom
Publisher Wiley-Blackwell
Language eng
Subject 2720 Hematology
Abstract Novel therapies with increased efficacy and decreased toxicity are desperately needed for the treatment of acute myeloid leukaemia (AML). The anti CD33 immunoconjugate, gemtuzumab ozogamicin (GO), was withdrawn with concerns over induction mortality and lack of efficacy. However a number of recent trials suggest that, particularly in AML with favourable cytogenetics, GO may improve overall survival. This data and the development of alternative novel monoclonal antibodies (mAb) have renewed interest in the area. Leukaemic stem cells (LSC) are identified as the subset of AML blasts that reproduces the leukaemic phenotype upon transplantation into immunosuppressed mice. AML relapse may be caused by chemoresistant LSC and this has refocused interest on identifying and targeting antigens specific for LSC. Several mAb have been developed that target LSC effectively in xenogeneic models but only a few have begun clinical evaluation. Antibody engineering may improve the activity of potential new therapeutics for AML. The encouraging results seen with bispecific T cell-engaging mAb-based molecules against CD19 in the treatment of B-cell acute lymphobalstic leukaemia, highlight the potential efficacy of engineered antibodies in the treatment of acute leukaemia. Potent engineered mAb, possibly targeting novel LSC antigens, offer hope for improving the current poor prognosis for AML.
Keyword Acute myeloid leukaemia
Antibody therapy
Novel leukaemia drugs
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: Non HERDC
School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 20 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 18 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 09 Apr 2014, 21:10:31 EST by Matthew Lamb on behalf of School of Medicine